The Repetitive Behavior Scale-Revised: independent validation in individuals with autism spectrum disorders.
ABSTRACT A key feature of autism is restricted repetitive behavior (RRB). Despite the significance of RRBs, little is known about their phenomenology, assessment, and treatment. The Repetitive Behavior Scale-Revised (RBS-R) is a recently-developed questionnaire that captures the breadth of RRB in autism. To validate the RBS-R in an independent sample, we conducted a survey within the South Carolina Autism Society. A total of 320 caregivers (32%) responded. Factor analysis produced a five-factor solution that was clinically meaningful and statistically sound. The factors were labeled "Ritualistic/Sameness Behavior," "Stereotypic Behavior," "Self-injurious Behavior," "Compulsive Behavior," and "Restricted Interests." Measures of internal consistency were high for this solution, and interrater reliability data suggested that the RBS-R performs well in outpatient settings.
- SourceAvailable from: Dalila Pinto[Show abstract] [Hide abstract]
ABSTRACT: There is an urgent need for expanding and enhancing autism spectrum disorder (ASD) samples, in order to better understand causes of ASD.Molecular Autism 01/2014; 5:34. · 5.49 Impact Factor
Conference Paper: Human Body-Parts Tracking for Fine-Grained Behavior Classification[Show abstract] [Hide abstract]
ABSTRACT: This paper discusses the usefulness of human body-parts tracking for acquiring subtle cues in social interactions. While many kinds of body-parts tracking algorithms have been proposed, we focus on particle filtering-based tracking using prior models, which have several advantages for researches on social interactions. As a first step for extracting subtle cues from videos of social interaction behaviors, the advantages, disadvantages, and prospective properties of the body-parts tracking using prior models are summarized with actual results.2013 IEEE International Conference on Computer Vision Workshops (ICCVW); 12/2013
- [Show abstract] [Hide abstract]
ABSTRACT: Elevated whole-blood serotonin and decreased plasma melatonin (a circadian synchronizer hormone that derives from serotonin) have been reported independently in patients with autism spectrum disorders (ASDs). Here, we explored, in parallel, serotonin, melatonin and the intermediate N-acetylserotonin (NAS) in a large cohort of patients with ASD and their relatives. We then investigated the clinical correlates of these biochemical parameters. Whole-blood serotonin, platelet NAS and plasma melatonin were assessed in 278 patients with ASD, their 506 first-degree relatives (129 unaffected siblings, 199 mothers and 178 fathers) and 416 sex-and age-matched controls. We confirmed the previously reported hyperserotonemia in ASD (40% (35–46%) of patients), as well as the deficit in melatonin (51% (45–57%)), taking as a threshold the 95th or 5th percentile of the control group, respectively. In addition, this study reveals an increase of NAS (47% (41–54%) of patients) in platelets, pointing to a disruption of the serotonin-NAS–melatonin pathway in ASD. Biochemical impairments were also observed in the first-degree relatives of patients. A score combining impairments of serotonin, NAS and melatonin distinguished between patients and controls with a sensitivity of 80% and a specificity of 85%. In patients the melatonin deficit was only significantly associated with insomnia. Impairments of melatonin synthesis in ASD may be linked with decreased 14-3-3 proteins. Although ASDs are highly heterogeneous, disruption of the serotonin-NAS–melatonin pathway is a very frequent trait in patients and may represent a useful biomarker for a large subgroup of individuals with ASD. Translational Psychiatry (2014) 4, e●●; doi:10.1038/tp.2014.120; published online xx xxx 2014 INTRODUCTION Autism spectrum disorders (ASDs) are complex, heterogeneous and multifactorial disorders characterized by impaired social communication and repetitive/stereotyped behaviors. The diag-nosis of ASD currently relies entirely on patient clinical evaluation.Translational psychiatry. 10/2014; 4.